RFK Jr. pledges to keep the US at the cen­ter of the biotech 'rev­o­lu­tion'

12 hours ago
Pharma

For­mer FDA sci­en­tist and psy­che­delics re­searcher hired as CDER deputy di­rec­tor

12 hours ago
People
FDA+

RFK Jr. says he did not com­mit to up­hold­ing ACIP ros­ter to se­cure Cas­sidy’s back­ing

12 hours ago
Pharma
FDA+

No­vo and Him­s' crossed wires

12 hours ago
Health Tech

Ex­clu­sive: Mikael Dol­sten joins gene edit­ing star­tup's board and eyes 'op­por­tu­ni­ties' with new FDA lead­ers

13 hours ago
People
Startups

Ex­clu­sive: FDA's Makary sought re­jec­tion of KalVista’s drug in an un­usu­al move by com­mis­sion­er, sources say

13 hours ago
FDA+

Rev­o­lu­tion inks up to $2B 'flex­i­ble' fund­ing deal to ad­vance RAS in­hibitor pipeline

16 hours ago
Financing
Deals

Nek­tar's mid-stage eczema da­ta de­liv­er key win in bid for com­pa­ny turn­around

16 hours ago
R&D

Ar­riVent plots next steps for lung can­cer drug; Neu­ron23's $96.5M raise

16 hours ago
News Briefing

UK gov­ern­ment blue­prints am­bi­tion to be a key life sci­ences hub 

20 hours ago
R&D
Pharma

Nu­va­lent clos­es in on FDA fil­ing for lung can­cer drug with topline Phase 1/2 da­ta

20 hours ago
R&D

The pol­i­tics of vac­ci­na­tion take cen­ter stage as RFK Jr.’s re­built CDC pan­el is set to meet

Yesterday
FDA+

Up­dat­ed: Am­gen plans low­er, slow­er Mar­i­Tide dos­es for obe­si­ty drug’s Phase 3

Yesterday
R&D

As­traZeneca, Dai­ichi Sankyo gain lung can­cer in­di­ca­tion for En­her­tu suc­ces­sor

Yesterday
Pharma
FDA+

Roche plans to pit next-gen he­mo­phil­ia A an­ti­body against Hem­li­bra in Phase 3

Yesterday
R&D

Supreme Court asks DOJ to weigh in on Hik­ma ‘skin­ny la­bel’ fight against Amarin

Yesterday
Pharma
Law

Ex­elix­is' pos­i­tive Phase 3 col­orec­tal can­cer da­ta boost stock

Yesterday
R&D

No­vo ends short-lived part­ner­ship with Hims over com­pound­ed obe­si­ty drugs

Yesterday
Startups
Pharma

For­ma­tion Bio’s up to €545M li­cens­ing deal with Sanofi; Ot­su­ka, Har­bour Bio­Med team up

Yesterday
News Briefing

Cidara near­ly dou­bles in val­ue as an­tivi­ral bi­o­log­ic pre­vents flu in mid-stage tri­al

Yesterday
R&D

Act­ing CDER chief is leav­ing af­ter al­most nine years at FDA

Yesterday
People
FDA+

Lil­ly’s bima­grum­ab boosts weight and fat loss when added to Novo's We­govy

Yesterday
R&D

Il­lu­mi­na to buy So­ma­Log­ic for $350M up­front, push­ing fur­ther in­to pro­teomics

Yesterday
Deals
Diagnostics

Up­dat­ed: Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, yet stock plum­mets

Yesterday
R&D
1234 Next page Last page
A service from the Financial Times